Affymetrix Supplies GeneChip(R) Technology to Veridex for Cancer Diagnostics Development
December 28 2004 - 8:30AM
PR Newswire (US)
Affymetrix Supplies GeneChip(R) Technology to Veridex for Cancer
Diagnostics Development Agreement Gives Veridex Non-Exclusive
Rights to GeneChip Technology SANTA CLARA, Calif., Dec. 28
/PRNewswire-FirstCall/ -- Affymetrix Inc. (NASDAQ:AFFX) announced
today that it has granted Veridex, LLC, a Johnson & Johnson
company, long-term and comprehensive access to its GeneChip(R)
technology to create and market in-vitro diagnostics for cancer.
The agreement, made under the Powered by Affymetrix(TM) program,
gives Veridex non-exclusive rights to Affymetrix' patented arrays,
instrumentation systems and planned improvements to these key
technologies. Financial terms of the agreement were not disclosed.
"Microarrays are an important technology for clinical oncology in
this era of molecular medicine," said Robert Lipshutz, Senior Vice
President Molecular Diagnostics and Emerging Markets at Affymetrix.
"We are pleased that Veridex chose Affymetrix technology and
believe that this continues to demonstrate that the leaders in the
diagnostic field are choosing the Affymetrix platform for genetic
analysis product development." Under the Powered by Affymetrix
program, Affymetrix provides technology and expertise for products
that are developed, branded and marketed by diagnostic companies.
This includes the GeneChip System 3000Dx, which has been granted
regulatory clearance by the U.S. Food and Drug Administration and
CE marked in the European Union for in-vitro diagnostic use. About
Affymetrix: Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip(R)
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,000 systems have been installed around the
world and nearly 3,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 900 employees
worldwide. All statements in this press release that are not
historical are "forward-looking statements" within the meaning of
Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix' "expectations," "beliefs,"
"hopes," "intentions," "strategies" or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to risks of the Company's ability to
achieve and sustain higher levels of revenue, higher gross margins,
reduced operating expenses, uncertainties relating to technological
approaches, manufacturing, product development, market acceptance
(including uncertainties relating to the use of Affymetrix
technology in diagnostics development), personnel retention,
uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to
sole source suppliers, uncertainties relating to FDA and other
regulatory approvals, competition, risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K for the year ended December 31, 2003 and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions, or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo,
and GeneChip are registered trademarks owned or used by Affymetrix
Inc. DATASOURCE: Affymetrix, Inc. CONTACT: media, Irma Gomez-Dib,
Public Relations Representative, +1-415-706-9155, or investors,
Doug Farrell, Vice President, Investor Relations, +1-408-731-5285,
both of Affymetrix, Inc. Web site: http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024